3 citations
,
October 2019 in “Dermatologic Therapy” Hair loss in men is mainly caused by hormones and genes, and while current treatments can slow it down, they can't fully stop it.
3 citations
,
December 2014 in “Journal of Clinical Oncology” Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.
1 citations
,
August 2022 in “Biomedicines” Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.
1 citations
,
January 2019 in “Elsevier eBooks” Neuroactive steroids may affect the risk and treatment of alcohol use disorders.
January 2026 in “Biology” Androgenetic alopecia is influenced by multiple genes and pathways, with genetic risk varying by population, and personalized treatments are being explored.
January 2026 in “International Journal of All Research Education & Scientific Methods” Alopecia is caused by various factors, and new treatments like gene editing and regenerative medicine offer hope for personalized hair regrowth solutions.
October 2025 in “Cosmetics” Genetic insights can lead to personalized treatments for acne, androgenetic alopecia, and alopecia areata.
June 2025 in “Pharmaceutics” Ethosomes with 30% ethanol effectively deliver dutasteride to hair follicles for treating hair loss.
June 2025 in “Journal of Drug Delivery Science and Technology” A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.
January 2025 in “Annals of Dermatology” New treatments for hair loss include low-dose oral minoxidil, light therapy, and innovative therapies targeting hair growth mechanisms.
May 2024 in “International Seven Journal of Multidisciplinary” More research is needed to better understand and treat Fibrosing Frontal Alopecia.
February 2018 in “InTech eBooks” Diagnosing and treating PCOS is complex due to differing criteria and requires a team approach.
November 2014 in “British Journal of Dermatology” Male hair loss is mainly due to thinner hair, not less hair.
November 2020 in “Postepy Dermatologii I Alergologii” Sulfotransferase SULT1A1 activity may predict minoxidil treatment success for hair loss.
April 2012 in “Informa Healthcare eBooks” AGA is a common hair loss affecting both genders, treated with various therapies to promote regrowth and slow thinning.
Female hair loss is often hereditary and can be treated with medication, hair transplants, and lasers.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
August 2012 in “Pharmaceutical Medicine” The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.
343 citations
,
October 2015 in “Endocrine Practice” The guide recommends specific methods for diagnosing PCOS and various treatments for its symptoms, while considering the health impacts on adolescents.
339 citations
,
February 2014 in “Journal of The American Academy of Dermatology” Most patients with frontal fibrosing alopecia are postmenopausal women, and treatments like finasteride and dutasteride can improve or stabilize the condition.
178 citations
,
April 2017 in “Journal of The American Academy of Dermatology” Minoxidil, finasteride, and low-level laser light therapy effectively treat hair loss.
124 citations
,
March 2012 in “JAMA” Testosterone's muscle-building effects do not require its conversion to DHT.
108 citations
,
February 2008 in “The Journal of urology/The journal of urology” Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
98 citations
,
January 2013 in “Journal of The American Academy of Dermatology” Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
66 citations
,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
55 citations
,
July 2016 in “Dermatologic Therapy” Multiple treatments work best for hair loss.
51 citations
,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.